Insights
Caring about Carers: Improving Consideration of the Burden of Informal Caring in HTA
11 April 2023
Through a three-part webinar series, commissioned and funded by Roche, OHE has explored the burdens on informal carers when providing unpaid care for loved ones.
Around The World in HTAs: Spain – Are We There Yet?
15 March 2023
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Laura Vallejo-Torres, University of Las Palmas de Gran Canaria, and Patricia Cubi-Molla, OHE, take us to Spain.
Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
15 February 2023
Gene therapies pose fresh challenges for discounting practice by HTA agencies. In this blog, we discuss why discounting is important for gene therapies, using a potential gene therapy for X-Linked Retinitis Pigmentosa (XLRP) as an example.
Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges
6 February 2023
During an engaging discussion of Professor Aidan Hollis’ prizewinning proposal with Professor Adrian Towse a range of potential benefits and remaining questions were explored.
Combination Therapies: A Step Forward to the Value Attribution Problem
4 January 2023
OHE convened a roundtable discussion to present and discuss recent work by OHE colleagues and collaborators on value attribution frameworks for combination therapies.
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
Programs to incentivise antibiotic R&D are underway in the UK and under consideration in the US, EU, Canada, and Japan. We have assessed the benefits and costs to the members of the G7/EU and project that all G7/EU members would see big payoffs ranging from 11:1 in the UK to 28:1 for the US and Japan. Global returns from reducing the 1.27m people dying each year from AMR are even higher.
ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”
8 December 2022
OHE, in collaboration with Pfizer, hosted an educational symposium entitled “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA methodologies Appropriately Value and Enable Access?”.
The World Needs New Antibiotics. A Proposed US Program to Develop Them Offers a High Pay-Off
16 November 2022
A Center for Global Development (CGD) paper authored by OHE’s Adrian Towse and CGD’s Rachel Silverman Bonnifield shows a very high expected return on investment (ROI)…
Improving the Measurement of Valued Output in Primary Care in England
1 August 2022
How can we identify efficiency variations across general practices and opportunities to improve their productivity if the measurement of output does not reflect the value produced?